Bordet Scientific Publications

Bordet Scientific Publications

Transcriptomic characterization of the histopathological growth patterns in breast cancer liver metastases.

Leduc S, Nguyen HL, Richard F, Zels G, Mahdami A, De Schepper M, Maetens M, Pabba A, Jaekers J, Latacz E, Bohlok A, Vanderheyden E, Van Brussel T, Boeckx B, Schepers R, Lambrechts D, Dirix L, Larsimont D, Vankerckhove S, Lucidi V, Topal B, Bachir I, Donckier V, Floris G, Vermeulen P, Desmedt C

Transcriptomic characterization of the histopathological growth patterns in breast cancer liver metastases.

Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.

Fernandez-Martinez A, Rediti M, Tang G, Pascual T, Hoadley KA, Venet D, Rashid NU, Spears PA, Islam MN, El-Abed S, Bliss J, Lambertini M, Di Cosimo S, Huobe J, Goerlitz D, Hu R, Lucas PC, Swain SM, Sotiriou C, Perou CM, Carey LA

Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.

Impact of scatter correction on personalized dosimetry in selective internal radiotherapy using <sup>166</sup>Ho-PLLA: a single-center study including Monte-Carlo simulation, phantom and patient imaging.

Collette B, Mannie-Corbisier M, Bucalau AM, Pauly N, Verset G, Moreno-Reyes R, Flamen P, Trotta N

Impact of scatter correction on personalized dosimetry in selective internal radiotherapy using <sup>166</sup>Ho-PLLA: a single-center study including Monte-Carlo simulation, phantom and patient imaging.

Optimal [ <sup>18</sup>F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.

Gebhart G, Keyaerts M, Guiot T, Flamen P, Ruiz-Borrego M, Stradella A, Bermejo B, Escriva-de-Romani S, Martínez LC, Ribelles N, Fernandez-Abad M, Albacar C, Colleoni M, Garrigos L, Atienza de Frutos M, Dalenc F, Prat A, Marmé F, Schmid P, Kerrou K, Braga S, Gener P, Sampayo-Cordero M, Cortés J, Pérez-García JM, Llombart-Cussac A

Optimal [ <sup>18</sup>F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.

Optimal [ <sup>18</sup>F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.

Gebhart G, Keyaerts M, Guiot T, Flamen P, Ruiz-Borrego M, Stradella A, Bermejo B, Escriva-de-Romani S, Martínez LC, Ribelles N, Fernandez-Abad M, Albacar C, Colleoni M, Garrigos L, Atienza de Frutos M, Dalenc F, Prat A, Marmé F, Schmid P, Kerrou K, Braga S, Gener P, Sampayo-Cordero M, Cortés J, Pérez-García JM, Llombart-Cussac A

Optimal [ <sup>18</sup>F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.
Erasme hospital

Erasmus Hospital

View all of Erasmus's scientific publications

Erasmus's academic publications
Huderf hospital

Queen Fabiola Children's Hospital

View all scientific publications from the Queen Fabiola Children's Hospital

Scientific publications from the Queen Fabiola Children's Hospital
Bordet hospital

Jules Bordet Institute

View all of Jules Bordet's scientific publications

Scientific publications by Jules Bordet